{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T13:34:21Z","timestamp":1772112861619,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020975","name":"UCB Pharma SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020975","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.farma.2023.11.004","type":"journal-article","created":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T14:55:48Z","timestamp":1703516148000},"page":"T51-T56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["[Translated article] Risk-sharing agreement based on health outcomes for the treatment of moderate\u2013severe psoriasis with certolizumab pegol"],"prefix":"10.1016","volume":"48","author":[{"given":"Andr\u00e9s Navarro","family":"Ruiz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando Toledo","family":"Alberola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Aceituno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.farma.2023.11.004_bb0005","doi-asserted-by":"crossref","first-page":"1583536","DOI":"10.1080\/20016689.2019.1583536","article-title":"The price of innovation - the role of drug pricing in financing pharmaceutical innovation. A conceptual framework","volume":"7","author":"Moreno","year":"2019","journal-title":"J Mark Access Health Policy."},{"key":"10.1016\/j.farma.2023.11.004_bb0010","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.socscimed.2014.11.003","article-title":"Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden","volume":"124","author":"Ferrario","year":"2015","journal-title":"Soc Sci Med."},{"key":"10.1016\/j.farma.2023.11.004_bb0015","series-title":"Framework for Analysing Risk in Health Technology Assessments and Its Application to Managed Entry Agreements","author":"Grimm","year":"2016"},{"issue":"5","key":"10.1016\/j.farma.2023.11.004_bb0020","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jval.2013.04.011","article-title":"Performance-based risk-sharing arrangements\u2014good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force","volume":"16","author":"Garrison","year":"2013","journal-title":"Value Health."},{"key":"10.1016\/j.farma.2023.11.004_bb0025","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.gaceta.2010.07.011","article-title":"Esquemas innovadores de mejora del acceso al mercado de nuevas tecnolog\u00edas: los acuerdos de riesgo compartido","volume":"24","author":"Esp\u00edn","year":"2010","journal-title":"Gaceta Sanitaria."},{"key":"10.1016\/j.farma.2023.11.004_bb0030","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/j.jval.2018.09.919","article-title":"PHP23-comparing risk sharing agreements in Catalonia with others EU countries","volume":"21","author":"Guarga","year":"2018","journal-title":"Value Health."},{"key":"10.1016\/j.farma.2023.11.004_bb0035","doi-asserted-by":"crossref","first-page":"S290","DOI":"10.1016\/j.jval.2019.04.1383","article-title":"PNS17 recent trends and evolution of risk sharing agreements from 2017 to 2019 in the United States","volume":"22","author":"Harris","year":"2019","journal-title":"Value Health."},{"issue":"2","key":"10.1016\/j.farma.2023.11.004_bb0040","doi-asserted-by":"crossref","first-page":"96","DOI":"10.31138\/mjr.32.2.96","article-title":"Biologic therapies and autoimmune phenomena","volume":"32","author":"Drosos","year":"2021","journal-title":"Mediter J Rheumatol."},{"issue":"8","key":"10.1016\/j.farma.2023.11.004_bb0045","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.adengl.2013.04.013","article-title":"Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment","volume":"104","author":"Puig","year":"2013","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas (English Edition)"},{"issue":"11","key":"10.1016\/j.farma.2023.11.004_bb0050","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s40261-021-01089-4","article-title":"Health economic assessment of optimal biological treatment for moderate-to-severe psoriasis","volume":"41","author":"Barker","year":"2021","journal-title":"Clin Drug Investig."},{"key":"10.1016\/j.farma.2023.11.004_bb0055","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ad.2018.02.015","article-title":"Manejo de la psoriasis moderada-grave en condiciones de pr\u00e1ctica habitual en el \u00e1mbito hospitalario espa\u00f1ol","volume":"109","author":"L\u00f3pez-Estebaranz","year":"2018","journal-title":"Actas Dermosifiliogr\u00e1ficas."},{"issue":"5","key":"10.1016\/j.farma.2023.11.004_bb0060","first-page":"504","article-title":"Prevalence of psoriasis in Spain in the age of biologics","volume":"105","author":"Ferrandiz","year":"2014","journal-title":"Actas Dermosifiliogr."},{"issue":"6","key":"10.1016\/j.farma.2023.11.004_bb0065","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ad.2022.01.024","volume":"113","author":"Carrascosa","year":"2022","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas."},{"key":"10.1016\/j.farma.2023.11.004_bb0070","author":"Academia Espa\u00f1ola de Dermatolog\u00eda y Veneroolog\u00eda (AEDV)"},{"key":"10.1016\/j.farma.2023.11.004_bb0075","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ad.2018.03.029","article-title":"PASI absoluto versus PASI relativo en la pr\u00e1ctica cl\u00ednica real","author":"del Alc\u00e1zar Viladomiu","year":"2019","journal-title":"Actas dermo-sifiliogr(Ed impr)."},{"key":"10.1016\/j.farma.2023.11.004_bb0080","author":"EMA. European Medicine Agency (EMA)"},{"issue":"4","key":"10.1016\/j.farma.2023.11.004_bb0085","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/bjd.19393","article-title":"Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2)","volume":"184","author":"Gordon","year":"2021","journal-title":"Br J Dermatol."},{"issue":"2","key":"10.1016\/j.farma.2023.11.004_bb0090","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaad.2018.04.012","article-title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48\u202fweeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)","volume":"79","author":"Gottlieb","year":"2018","journal-title":"J Am Acad Dermatol."},{"issue":"2","key":"10.1016\/j.farma.2023.11.004_bb0095","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaad.2018.04.013","article-title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48\u202fweeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)","volume":"79","author":"Lebwohl","year":"2018","journal-title":"J Am Acad Dermatol."},{"issue":"3","key":"10.1016\/j.farma.2023.11.004_bb0100","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13409","article-title":"Clinical efficacy and safety of certolizumab pegol in cutaneous symptoms on psoriasis in patients with psoriatic arthritis: a retrospective analysis in real life","volume":"33","author":"Dattola","year":"2019","journal-title":"Dermatol Ther."},{"issue":"8","key":"10.1016\/j.farma.2023.11.004_bb0105","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.ad.2019.01.023","article-title":"Efectividad de certolizumab pegol en psoriasis en una cohorte de pacientes con artritis psori\u00e1sica","volume":"111","author":"Reina","year":"2020","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas."},{"key":"10.1016\/j.farma.2023.11.004_bb0110","author":"SESCAM"},{"key":"10.1016\/j.farma.2023.11.004_bb0115","author":"INE"},{"issue":"3","key":"10.1016\/j.farma.2023.11.004_bb0120","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.healthpol.2020.11.009","article-title":"Impact of a risk-sharing agreement in rheumatoid arthritis in Spain","volume":"125","author":"Garc\u00eda-Collado","year":"2021","journal-title":"Health Policy."},{"issue":"6","key":"10.1016\/j.farma.2023.11.004_bb0125","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1080\/14737167.2019.1587296","article-title":"The current performance-linked and risk sharing agreement scene in the Spanish region of Catalonia","volume":"19","author":"Darb\u00e0","year":"2019","journal-title":"Exp Rev Pharmacoecon Outcomes Res."},{"key":"10.1016\/j.farma.2023.11.004_bb0135","first-page":"10","article-title":"Implementation and results of a risk-sharing scheme for enzyme replacement therapy in lysosomal storage diseases","volume":"44","author":"Edo-Solsona","year":"2020","journal-title":"Farmacia Hospitalaria."},{"key":"10.1016\/j.farma.2023.11.004_bb0140","year":"2015","journal-title":"DiarioFarma."},{"issue":"4","key":"10.1016\/j.farma.2023.11.004_bb0145","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s13555-017-0208-z","article-title":"Certolizumab pegol in the treatment of psoriasis and psoriatic arthritis: preliminary real-life data","volume":"7","author":"Dattola","year":"2017","journal-title":"Dermatol Ther."},{"issue":"3","key":"10.1016\/j.farma.2023.11.004_bb0150","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14929","article-title":"Certolizumab pegol in the treatment of psoriasis: real-life data","volume":"34","author":"Turkmen","year":"2021","journal-title":"Dermatol Ther."},{"issue":"3","key":"10.1016\/j.farma.2023.11.004_bb0155","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/12034754221078203","article-title":"Certolizumab pegol use in the treatment of moderate-to-severe psoriasis: real-world data from two Canadian Centers","volume":"26","author":"Vender","year":"2022","journal-title":"J Cutan Med Surg."},{"issue":"7","key":"10.1016\/j.farma.2023.11.004_bb0160","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1080\/09546634.2019.1605143","article-title":"Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis","volume":"31","author":"Carubbi","year":"2020","journal-title":"J Dermatol Treat."},{"issue":"2","key":"10.1016\/j.farma.2023.11.004_bb0165","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4161\/mabs.2.2.11271","article-title":"Certolizumab pegol","volume":"2","author":"Goel","year":"2010","journal-title":"MAbs."},{"issue":"1","key":"10.1016\/j.farma.2023.11.004_bb0170","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s13555-022-00861-4","article-title":"Long-term health-related quality of life in patients with plaque psoriasis treated with certolizumab pegol: three-year results from two randomised phase 3 studies (CIMPASI-1 and CIMPASI-2)","volume":"13","author":"Gisondi","year":"2023","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"1","key":"10.1016\/j.farma.2023.11.004_bb0175","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000365390","article-title":"Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data","volume":"230","author":"Basra","year":"2015","journal-title":"Dermatology."}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634323009303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634323009303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:18:32Z","timestamp":1761106712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634323009303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1130634323009303"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2023.11.004","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Risk-sharing agreement based on health outcomes for the treatment of moderate\u2013severe psoriasis with certolizumab pegol","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2023.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2023.07.016","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}